Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...

Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Bio ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

M. Gillheeney, Sr. continued: “We expect to meet a key strategic milestone in 2025 by delivering the ReNu BLA submission by the end of the year. We believe this is a transformational opportunity for ...

Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Scholar Rock Holding Corporation. ( NASDAQ: SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial ...

The company posted adjusted earnings per share of $0.04 for the fourth quarter, beating the analyst estimate of -$0.01. Revenue came in at $126.7 million, surpassing the consensus forecast of $109.6 ...

Gut health is already shaping the future of food and beverage. Now, research on the gut’s influence over mental health, look ...